Acadia Pharmaceuticals 对比 ANI Pharmaceuticals
可添加、更换或移除公司，最多四家。
简而言之
- Acadia Pharmaceuticals 规模更大:2025 财年营收 $1.1B，ANI Pharmaceuticals 为 $883M。
- ANI Pharmaceuticals 营收增长更快(43.8%，对方为 11.9%)。
- ANI Pharmaceuticals 每一美元销售额中留下的营业利润更多(营业利润率 12.6%，对方为 9.8%)。
- ANI Pharmaceuticals 将更多销售额转化为自由现金流(自由现金流利润率 19.4%，对方为 9.8%)。
- 投资者愿为 ANI Pharmaceuticals 每一美元的盈利支付更高价格：市盈率 15.7x，而 Acadia Pharmaceuticals 为 8.8x。
| 最近财年 | ACAD · FY25 | ANIP · FY25 |
|---|---|---|
| 规模 | ||
| 市值 | $3.4B | $1.6B |
| 营收 | $1.1B | $883M |
| 自由现金流 | $105M | $171M |
| 净利润 | $391M | $78.3M |
| 增长 | ||
| 营收增长 | 11.9% | 43.8% |
| 5年增长率 | 19.4% | 33.5% |
| 股数变化 | 2.1% | 9.9% |
| 盈利能力 | ||
| 毛利率 | 91.7% | — |
| 营业利润率 | 9.8% | 12.6% |
| 净利率 | 36.5% | 8.9% |
| 自由现金流利润率 | 9.8% | 19.4% |
| 资本回报率 | — | 15.9% |
| 股本回报率 | 39.9% | 16.6% |
| 资产负债表 | ||
| 净债务 | — | $23.7M |
| 净债务 / EBITDA | — | 0.1x |
| 股息与回购 | $0.0M | $13.4M |
| 估值与质量 | ||
| 市盈率 | 8.8x | 15.7x |
| Piotroski F 分数 | — | 6 |
FY16
ACAD $17.3M
ANIP $129M
FY17
ACAD $125M
ANIP $177M
FY18
ACAD $224M
ANIP $202M
FY19
ACAD $339M
ANIP $207M
FY20
ACAD $442M
ANIP $209M
FY21
ACAD $484M
ANIP $216M
FY22
ACAD $517M
ANIP $316M
FY23
ACAD $726M
ANIP $487M
FY24
ACAD $958M
ANIP $614M
FY25
ACAD $1.1B
ANIP $883M
ACAD
ANIP
FY16
ACAD −1,574.1%
ANIP 15.6%
FY17
ACAD −234.1%
ANIP 16.0%
FY18
ACAD −110.6%
ANIP 17.5%
FY19
ACAD −72.7%
ANIP 7.9%
FY20
ACAD −64.9%
ANIP −7.7%
FY21
ACAD −35.2%
ANIP −18.4%
FY22
ACAD −43.2%
ANIP −11.2%
FY23
ACAD −10.1%
ANIP 9.7%
FY24
ACAD 24.1%
ANIP 0.1%
FY25
ACAD 9.8%
ANIP 12.6%
ACAD
ANIP
FY16
ACAD −$210M
ANIP $22.9M
FY17
ACAD −$219M
ANIP $29.1M
FY18
ACAD −$170M
ANIP $61.3M
FY19
ACAD −$152M
ANIP $39.0M
FY20
ACAD −$144M
ANIP $9.1M
FY21
ACAD −$127M
ANIP $0.8M
FY22
ACAD −$114M
ANIP −$40.1M
FY23
ACAD $16.7M
ANIP $110M
FY24
ACAD $157M
ANIP $47.8M
FY25
ACAD $105M
ANIP $171M
ACAD
ANIP
FY16
ACAD —
ANIP 5.3%
FY17
ACAD —
ANIP 5.3%
FY18
ACAD —
ANIP 11.0%
FY19
ACAD —
ANIP 5.8%
FY20
ACAD —
ANIP −3.6%
FY21
ACAD —
ANIP −7.0%
FY22
ACAD —
ANIP −5.2%
FY23
ACAD —
ANIP 8.5%
FY24
ACAD —
ANIP 0.1%
FY25
ACAD —
ANIP 15.9%
ACAD
ANIP
各公司最近一个财年的数据；各公司财年结束月份不同。在越高(或越低)明显越好的行中，突出显示最佳值。不构成投资建议。